Hikma Pharmaceuticals US unit launches injectable cancer treatment

Writer, Stock Market Wire
Tuesday, January 29, 2019 - 13:07

Hikma Pharmaceuticals said its US unit had launched its cancer treatment Mitomycin for injection.

The treatment was not recommended as single-agent, primary therapy but had been shown to be useful in treating disseminated adenocarcinoma of the stomach or pancreas in proven combinations with other approved chemotherapeutic agents.

It was also useful as palliative treatment when other modalities had failed.

'We are excited to add Mitomycin for injection to our oncology portfolio in the US, improving patients' access to this important medicine,' injectables president Riad Mechlaoui said.

'This demonstrates the successful execution of our strategy to expand our portfolio in key therapeutic areas.'

At 1:07pm: (LON:HIK) Hikma Pharmaceuticals PLC share price was +19.25p at 1529.75p


Related content

Hikma Pharmaceuticals launches pre-filled syringes in US

Generic drugs company Hikma Pharmaceuticals said it had launched a new pre-filled syringe capability in the US.

The first medicine available was is Heparin sodium...

Tue, 17/09/2019 - 09:16


Marks & Spencer in danger of losing FTSE 100 place

Author: 

Next week we will know which stocks are joining the FTSE 100 index of leading UK companies on 23 September and which have been relegated...

Thu, 29/08/2019 - 00:00


Marks & Spencer ready to check-out of FTSE 100 in latest index reshuffle

We have already had four changes to the FTSE 100’s make-up in 2019, and further changes look likely at the reshuffle that will take place...

Wed, 28/08/2019 - 09:59


Broker Forecast - Barclays Capital issues a broker note on Hikma Pharmaceuticals PLC

Barclays Capital today reaffirms its equal weight investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and raised its price target to 1900p (from 1800p).

Broker Forecasts...

Tue, 20/08/2019 - 08:40


Broker Forecast - Peel Hunt issues a broker note on Hikma Pharmaceuticals PLC

Peel Hunt today reaffirms its hold investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and raised its price target to 2050p (from 1870p).

Broker Forecasts data...

Fri, 09/08/2019 - 09:30